Skip to Main content Skip to Navigation
Journal articles

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response

Abstract : The antibody-dependent cellular cytotoxicity (ADCC) effector function of natural killer (NK) cells is one of the known mechanisms of action for rituximab-based anti-cancer immunotherapy. Inhibition of the ADCC function of NK cells through interactions between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA class I ligands is associated with resistance of cancers to rituximab. In this study, we deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma (NHL) patients. We highlight that an HLA environment with limited KIR ligands is beneficial to promoting a higher frequency of KIR+ NK cells including both educated and uneducated NK cells, two NK cell compartments that demonstrate higher rituximab-dependent degranulation than KIR- NK cells. In contrast, a substantial KIR ligand environment favors a higher frequency of poorly effective KIR- NK cells and numerous functional KIR/HLA inhibitions of educated KIR+ NK cells. These phenomena explain why NHL patients with limited KIR ligands respond better to rituximab. In this HLA environment, CD16 polymorphism appears to have a collateral effect. Furthermore, we show the synergic effect of KIR2DS1, which strongly potentiates NK cell ADCC from C2- blood donors against C2+ target cells. Taken together, these results pave the way for stronger prediction of rituximab responses for NHL patients. HLA class I typing and peripheral blood KIR+ NK cell frequency could be simple and useful markers for predicting rituximab response.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03287975
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Friday, July 16, 2021 - 9:20:28 AM
Last modification on : Wednesday, April 27, 2022 - 3:50:22 AM
Long-term archiving on: : Sunday, October 17, 2021 - 6:12:16 PM

File

OncoImmunol2021Eq1.pdf
Publication funded by an institution

Identifiers

Citation

Dhon Roméo Makanga, Maxime Jullien, Gaëlle David, Nolwenn Legrand, Catherine Willem, et al.. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. OncoImmunology, Taylor & Francis, 2021, 10 (1), pp.1936392. ⟨10.1080/2162402x.2021.1936392⟩. ⟨inserm-03287975⟩

Share

Metrics

Record views

35

Files downloads

28